Home > Journals > Minerva Endocrinologica > Past Issues > Articles online first > Minerva Endocrinologica 2017 Sep 25



Publication history
Cite this article as


A Journal on Endocrine System Diseases

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383



Minerva Endocrinologica 2017 Sep 25

DOI: 10.23736/S0391-1977.17.02742-0


language: English

Role of positron emission tomography in thyroid and neuroendocrine tumours

Giorgio TREGLIA 1, 2, 3 , Alexander S. KROISS 4, Arnoldo PICCARDO 5, Filippo LOCOCO 6, Prasanna SANTHANAM 7, Alessio IMPERIALE 8, 9, 10

1 Department of Nuclear Medicine and PET/CT Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; 2 Health Technology Assessment, Innovation Area, General Directorate, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 3 Department of Nuclear Medicine and Molecular Imaging, CHUV University Hospital, Lausanne, Switzerland; 4 Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria; 5 Department of Nuclear Medicine, E.O. Ospedali Galliera, Genoa, Italy; 6 Unit of Thoracic Surgery, Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy; 7 Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 8 Biophysics and Nuclear Medicine, University Hospitals of Strasbourg, Strasbourg, France; 9 ICube, UMR 7357 University of Strasbourg/CNRS, Strasbourg, France; 10 FMTS, Faculty of Medicine, University of Strasbourg, Strasbourg, France


BACKGROUND: Positron emission tomography (PET) is an established imaging method in oncology. PET/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI) are hybrid techniques which combine morphological information obtained by CT and MRI with functional data provided by PET. Several radiotracers evaluating different metabolic pathways or receptor status can be used as PET radiotracers to assess endocrine tumours such as thyroid tumours or neuroendocrine neoplasms (NENs). This review is focused to describe the role of PET imaging using different radiotracers in patients with thyroid tumours and NENs.
METHODS: The role of PET imaging with different radiotracers in several endocrine tumours including thyroid tumours, gastroenteropancreatic neoplasms (GEP-NENs), lung neuroendocrine neoplasms (LNENs), pheochromocytomas (PCC) and paragangliomas (PGL), and multiple endocrine neoplasia (MEN) syndromes has been described.
RESULTS: Fluorine-18 fluorodeoxyglucose (18F-FDG) PET evaluating the glucose metabolism provides useful diagnostic and prognostic information in patients with thyroid tumours. Iodine-124 (124I) assessing the iodine metabolism (124I) PET may be used for dosimetry and diagnostic purposes in thyroid tumours. In patients with NENs specific radiotracers can be used for diagnostic purposes such as somatostatin analogues labeled with gallium-68 (68Ga-DOTA-peptides) evaluating somatostatin receptor expression and fluorine-18 fluorodihydroxyphenylalanine (18F- FDOPA) assessing the uptake, decarboxylation and storage of amine precursors. One advantage of 68Ga-DOTA-peptides PET is to select patients with well-differentiated and inoperable NENs for peptide receptor radionuclide therapy (PRRT). 18F-FDG PET may provide useful prognostic information in patients with high-grade NENs.
CONCLUSIONS: PET imaging with different radiotracers is a useful functional imaging technique in the work-up of several endocrine tumours.

KEY WORDS: PET - Thyroid - Neuroendocrine - Nuclear medicine - Imaging

top of page

Publication History

Article first published online: September 25, 2017
Manuscript accepted: September 20, 2017
Manuscript received: September 13, 2017

Cite this article as

Treglia G, Kroiss AS, Piccardo A, Lococo F, Santhanam P, Imperiale A. Role of positron emission tomography in thyroid and neuroendocrine tumours. Minerva Endocrinol 2017 Sep 25. DOI: 10.23736/S0391-1977.17.02742-0

Corresponding author e-mail